US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Global Partners LP

49.76

+0.85001.74%

Post-market: 49.760.00000.00%19:24 EDT

Volume:17.13K

Turnover:854.34K

Market Cap:1.68B

PE:20.65

High:51.08

Open:49.27

Low:48.92

Close:48.91

Loading ...

Overview Company News Filings

Lexaria's Human GLP-1 Study #5 Begins Dosing

ACCESS Newswire

DexCom (DXCM) Slid on Poor Execution and GLP-1 Drug Disruption Concerns

Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation

ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies

Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

GLP J-REIT to Acquire Acacia SPC's Fifth Preferred Securities for 112 Million Yen

MT Newswires Live

GLP-1s are driving returns on R&D investments for Big Pharma, report says

GLP-1s boosts pharma R&D projected return on investment: Deloitte

Novo Nordisk strikes $2 billion deal with a Chinese company making a GLP-1 drug

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

BRIEF-Global Partners LP enters eleventh amendment to credit, security agreements

Global Partners Lp - on March 20, Enters Eleventh Amendment to Credit and Security Agreements - SEC Filing

THOMSON REUTERS

Allurion announces initial results from Allurion Program-GLP-1 combo

Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence

“GLP-1 Is a Curse Word!” – Jim Cramer on PepsiCo (PEP)’s Snack Struggles

Is Global Partners LP (GLP) The Best Pipeline and MLP Stock to Invest In According to Analysts?

PepsiCo, Inc. (PEP): “GLP-1 Is a Curse Word for Pepsi!” – Jim Cramer’s Take on the Snack Giant

Jim Cramer Sees General Mills (GIS) Struggling as GLP-1 Weight Loss Drugs Take Over

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/GLP/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GLP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLP\",,,,,undefined,":{"symbol":"GLP","market":"US","secType":"STK","nameCN":"Global Partners LP","latestPrice":49.76,"timestamp":1745352000000,"preClose":48.91,"halted":0,"volume":17130,"hourTrading":{"tag":"盘后","latestPrice":49.76,"preClose":49.76,"latestTime":"19:24 EDT","volume":1022,"amount":50852.97,"timestamp":1745364289065},"delay":0,"floatShares":25096277,"shares":33668256,"eps":2.41,"marketStatus":"Closed","change":0.85,"latestTime":"04-22 16:00:00 EDT","open":49.27,"high":51.08,"low":48.915,"amount":854343.0589200001,"amplitude":0.044265,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.41,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745395200000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1127966400000,"exchange":"NYSE","adjPreClose":48.91,"postHourTrading":{"tag":"盘后","latestPrice":49.76,"preClose":49.76,"latestTime":"19:24 EDT","volume":1022,"amount":50852.97,"timestamp":1745364289065},"volumeRatio":0.552114,"impliedVol":0.4676,"impliedVolPercentile":0.64},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLP\",,,,,undefined,":{"symbol":"GLP","floatShares":25096277,"roa":"4.19%","roe":"14.20%","lyrEps":2.44604,"volumeRatio":0.552114,"shares":33668256,"dividePrice":2.96,"high":51.08,"amplitude":0.044265,"preClose":48.91,"low":48.915,"week52Low":37.0034,"pbRate":"2.61","psRate":"0.10","week52High":60,"institutionHeld":0.407,"latestPrice":49.76,"eps":2.41,"divideRate":0.059486,"volume":17130,"delay":0,"ttmEps":2.41,"open":49.27,"prevYearClose":46.55,"prevWeekClose":50.77,"prevMonthClose":53.38,"prevQuarterClose":53.38,"fiveDayClose":49.13,"twentyDayClose":52.68,"sixtyDayClose":51.42},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GLP\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524497651","title":"Lexaria's Human GLP-1 Study #5 Begins Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2524497651","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524497651?lang=en_us&edition=fundamental","pubTime":"2025-04-02 21:05","pubTimestamp":1743599100,"startTime":"0","endTime":"0","summary":"Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide. KELOWNA, BC / ACCESS Newswire / April 2, 2025 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, is pleased to announce that dosing has begun as scheduled in its human study GLP-1-H25-5  that is comparing oral DehydraTECH-liraglutide to injected Saxenda-branded liraglutide.On November 20, 2024, Lexaria reported on an earlier 12-week study in rodents which showed that with unlimited food available, oral DehydraTECH-liraglutide demonstrated a 5.88% weight reduction and an 11.54% blood sugar reduction as compared to baseline.The current Study is designed to test pharmacokinetics   and adverse events in humans. Lexaria has previously shown in other GLP-1 PK studies in humans, that certain oral DehydraTECH formulations demonstrated superior bloodstream delivery, as well as reduced adverse events as compared to the oral semaglutide and injectable tirzepati","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexarias-human-glp-1-study-130500653.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LEXX","GLP","BK4144","LEXXW","BK4007","BK4590"],"gpt_icon":0},{"id":"2524796114","title":"DexCom (DXCM) Slid on Poor Execution and GLP-1 Drug Disruption Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2524796114","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524796114?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:59","pubTimestamp":1743512353,"startTime":"0","endTime":"0","summary":"Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A copy of the same can be downloaded here. Select Growth primarily targets U.S. companies that are leading the way in crucial areas of positive structural transformation within the economy. The fund returned 8.8%  in the fourth quarter compared to 7.1% return for the benchmark, the Russell 1000 Growth Index. The fund returned 24.3% over the one year period compared to 33.4% return for the Index. You can check the fund’s top 5 holdings to know more about its best picks for 2024.\"DexCom, Inc.  was a significant detractor from absolute and relative results in 2024, which we attribute to a combination of poor execution and fears of disruption by GLP-1 drugs.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dexcom-dxcm-slid-poor-execution-125913782.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4504","IE00BMPRXN33.USD","USJW.SI","IE00BMPRXR70.SGD",".IXIC","BK4082","BK4534","LU2125909247.SGD","MNQmain","QID","BK4585","BK4590","GLP","QLD","TQQQ","LU0354030511.USD","DXCM","LU0354030438.USD","TSYW.SI","LU2433249047.HKD","USAW.SI","LU2211815571.USD","SQQQ","PSQ","NQmain","BK4144","LU1923622614.USD","LU2125909593.SGD","LU1323610961.USD","BK4551","BK4548","NVIW.SI","BK4588","LU0266013472.USD"],"gpt_icon":1},{"id":"2524019416","title":"Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2524019416","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524019416?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:00","pubTimestamp":1743505200,"startTime":"0","endTime":"0","summary":"New REVEAL-1 study results show early signs of weight maintenance after GLP-1 discontinuation REMAIN-1 pivotal study now more than 50% enrolled; midpoint data analysis anticipated in Q3 2025 BURLINGTO","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3053157/0/en/Fractyl-Health-Reports-Positive-Early-Data-Showing-Revita-Has-Potential-to-Prevent-Weight-Regain-After-GLP-1-Discontinuation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDE","BK4590","BK4082","GUTS","BK4144","GLP"],"gpt_icon":0},{"id":"2523946977","title":"ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2523946977","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523946977?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:05","pubTimestamp":1743422700,"startTime":"0","endTime":"0","summary":"Enhanced strategic focus for TAEUS addresses a large, unmet global need for a cost-effective tool for monitoring liver health at the point of patient care. ENDRA’s management has thoroughly evaluated the Company’s technical capabilities and go-to-market strategy for TAEUS Liver and determined that this new target market opportunity is far larger and more viable than its prior focus on hepatology and radiology markets, noting that metabolic diseases are an upstream phenomenon that lead to multiple risk factors including those specific to liver diseases. With this pivot toward metabolic health, ENDRA’s revised mission is to develop and market an accurate, simple-to-use, inexpensive, point-of-care test – essentially a \"blood pressure cuff\" – for the assessment and management of steatotic liver disease .","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/endra-life-sciences-announces-enhanced-120500159.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","GLP","BK4590","BK4023","BK4596","STRK","BK4144","BK4600","NDRA","BK4595","BK4516","BK4588","BK4585"],"gpt_icon":1},{"id":"2523945625","title":"Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist","url":"https://stock-news.laohu8.com/highlight/detail?id=2523945625","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523945625?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:00","pubTimestamp":1743422400,"startTime":"0","endTime":"0","summary":"– Data Further Advance Understanding of VASCEPA/VAZKEPA Potential Mechanism of Action and Utility as A Complementary Therapy for Residual Risk Reduction in Combination with Statins in Important Patien","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052239/18362/en/Amarin-Highlights-Recent-Data-Presented-at-ACC-25-Evaluating-Mechanistic-Effects-of-Eicosapentaenoic-Acid-EPA-in-Lp-a-Enriched-Plasma-and-in-Combination-with-GLP-1-Agonist.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TG","IPE","BK4590","GLP","AMRN","BK4144","BK4090","BK4153","BK4139"],"gpt_icon":0},{"id":"2522581083","title":"Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102","url":"https://stock-news.laohu8.com/highlight/detail?id=2522581083","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522581083?lang=en_us&edition=fundamental","pubTime":"2025-03-27 04:05","pubTimestamp":1743019500,"startTime":"0","endTime":"0","summary":"-  RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalence –。- Both groups demonstrated comparable weight loss with less variability observed with RT-114 compared to subcutaneous PG-102 –。- Phase 1 clinical trial of subcutaneous PG-102 demonstrated weight loss in obese patients, with an average reduction of 4.8% and up to 8.7% following five weeks of dosing -. - Data bolster expanding body of evidence of the RaniPill platform’s potential to facilitate oral delivery of multiple obesity treatments including previously announced semaglutide -. - Phase 1 clinical study for RT-114 for the treatment of obesity expected to initiate in mid- 2025 -. ProGen recently announced preliminary results of the repeat-dose portion  of its Phase 1 study where SC PG-102 demonstrated weight loss in obese subjects, with an average reduction of 4.8% and up to 8.7% following five week","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rani-therapeutics-announces-preclinical-data-200500857.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","RANI","GLP","PG"],"gpt_icon":0},{"id":"2522051908","title":"Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2522051908","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522051908?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:40","pubTimestamp":1742992800,"startTime":"0","endTime":"0","summary":"Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials. SARASOTA, FL, March 26, 2025  -- Silo Pharma, Inc.  , a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced first dosing in an investigational new drug -enabling GLP -compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder .Forward-Looking StatementsThis news release contains \"forward-looking statements\" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual result","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/silo-pharma-achieves-key-milestone-124000759.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPC","BK4135","BK4202","BK4139","GLP","SILO","BK4590","CNS","BK4144"],"gpt_icon":0},{"id":"2522583228","title":"GLP J-REIT to Acquire Acacia SPC's Fifth Preferred Securities for 112 Million Yen","url":"https://stock-news.laohu8.com/highlight/detail?id=2522583228","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522583228?lang=en_us&edition=fundamental","pubTime":"2025-03-26 08:02","pubTimestamp":1742947355,"startTime":"0","endTime":"0","summary":"GLP J-REIT  will acquire the fifth preferred securities issued by Acacia Special Purpose Company for 112 million yen, according to a Tuesday filing on the Tokyo Stock Exchange.The acquisition, scheduled for March 28, will be funded with cash on hand.The total planned issuance of preferred securities by Acacia SPC has been adjusted, with the sixth issuance reduced to 131 million yen from 152 million yen and the seventh issuance increased to 1.36 billion yen from 1.32 billion yen.The total issuance across all seven rounds is expected to reach 1.92 billion yen, or about 20.1% of the total preferred securities issued and to be issued by the SPC.Price : $122300.00, Change: $-700, Percent Change: -0.57%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4144","CFA.SI","REIT","SPC","GLP","ACIA","BK4590"],"gpt_icon":0},{"id":"2522988420","title":"GLP-1s are driving returns on R&D investments for Big Pharma, report says","url":"https://stock-news.laohu8.com/highlight/detail?id=2522988420","media":"Quartz","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522988420?lang=en_us&edition=fundamental","pubTime":"2025-03-26 02:26","pubTimestamp":1742927160,"startTime":"0","endTime":"0","summary":"In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, California. - Image: Mario Tama / Staff . Big Pharma is expected to see big returns from its investment in a class of drugs made famous by Novo Nordisk’s  popular diabetes drug Ozempic.Deloitte’s annual report, Measuring the Return from Pharmaceutical Innovation, found that GLP-1 drugs could fuel significant returns on research and development investments made last year by major drugmakers. The consulting firm analyzed the projected internal rate of return for late-stage pipeline assets across the 20 leading pharma companies.GLP-1 drugs mimic hormones that regulate blood sugar and suppress appetite, making them highly sought after for treating obesity and Type 2 diabetes. The surging demand has propelled Eli Lilly  and Novo Nordisk into becoming the largest pharma companies in the world. Eli Lilly’s weight-loss drug Zepbound generated $4.9 billion in annual revenu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/glp-1s-driving-returns-r-182600084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1712237335.SGD","LU0689472784.USD","LU1623119135.USD","LU0823416689.USD","LU0154236417.USD","IE0004445239.USD","LU2357305700.SGD","LU2237443465.HKD","LU2468319806.SGD","BK4581","LU2461242641.AUD","SGXZ99366536.SGD","LU0094547139.USD","LU1093756325.SGD","LU1267930730.SGD","LU1974910355.USD","LU0256863902.USD","NVO","SG9999018857.SGD","LU0820561909.HKD","LU0096364046.USD","LLY","SG9999018865.SGD","LU2237443549.SGD","LU2063271972.USD","GLP","LU0385154629.USD","BK4516","LU2602419157.SGD","LU1291159041.SGD","LU0417517546.SGD","LU1551013425.SGD","BK4590","LU2265009873.SGD","LU0097036916.USD","SG9999015978.USD","LU0109391861.USD","LU2324357040.USD","SG9999015986.USD","LU1720051108.HKD","LU1868837136.USD","IE00BK4W5M84.HKD","LU1061106388.HKD","LU1989771016.USD","LU0203202063.USD","LU1366192091.USD","LU2023250504.SGD","SG9999015952.SGD","SG9999014914.USD","LU2264538146.SGD"],"gpt_icon":1},{"id":"2522052598","title":"GLP-1s boosts pharma R&D projected return on investment: Deloitte","url":"https://stock-news.laohu8.com/highlight/detail?id=2522052598","media":"Yahoo Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522052598?lang=en_us&edition=fundamental","pubTime":"2025-03-25 12:00","pubTimestamp":1742875241,"startTime":"0","endTime":"0","summary":"Popular diabetes and weight-loss drugs known as GLP-1s are helping to boost the biopharma sector's return on investment this year, according to a new report from consulting firm Deloitte.Companies that are developing drug candidates that could compete with the two market leaders, Novo Nordisk  and Eli Lilly , and their blockbuster weight-loss and diabetes drugs are adding more value to research in the sector, said Deloitte.The report shows the R&D returns for 2024 were 5.9%, up from 4.1% in 2023. Without GLP-1s, the returns for R&D would have dropped to 3.8% in 2024.ROI isn't the only area in which GLP-1s are boosting the sector. Peak sales forecasts are also benefiting. Average peak sales projected per asset have increased to $510 million. But without GLP-1s, that average drops to $370 million.Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/glp-1s-boosts-pharma-rd-projected-return-on-investment-deloitte-040041685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999015978.USD","LU0006306889.USD","LU1069344957.HKD","LU0354030438.USD","LU1280957306.USD","IE00BK4W5M84.HKD","IE00BK4W5L77.USD","SG9999014914.USD","LU1814569148.SGD","GLP","LU0882574139.USD","LU1093756168.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU0058720904.USD","LU2023250504.SGD","SG9999014880.SGD","LU0097036916.USD","SG9999015952.SGD","BK4516","LU2265009873.SGD","LU0640476718.USD","IE0002141913.USD","LU1127390331.HKD","SG9999018865.SGD","SG9999014898.SGD","LU1988902786.USD","LU1551013425.SGD","LU2461242641.AUD","LU0385154629.USD","LU1551013342.USD","LLY","LU2491050071.SGD","NVO","SG9999015945.SGD","LU2357305700.SGD","LU2237443895.HKD","LU1989771016.USD","LU1868837300.USD","LU2237443465.HKD","LU0154236417.USD","SGXZ31699556.SGD","BK4007","SG9999018857.SGD","BK4599","LU0672654240.SGD","LU1093756325.SGD","LU0203201768.USD","IE0004445239.USD","IE00BFTCPJ56.SGD"],"gpt_icon":1},{"id":"2521538745","title":"Novo Nordisk strikes $2 billion deal with a Chinese company making a GLP-1 drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2521538745","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521538745?lang=en_us&edition=fundamental","pubTime":"2025-03-24 18:55","pubTimestamp":1742813700,"startTime":"0","endTime":"0","summary":"Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player.Novo Nordisk said it's paying $200 million upfront and up to $1.8 billion in milestone payments to United Laboratories International for the right to license a drug, outside of China that is in early-stage development to treat obesity, Type 2 diabetes and other diseases.The candidate, currently called UBT251, is what's called a triple agonist of the receptors for GLP-1, GIP, and glucagon. In a Phase 1 trial, the highest dose group achieved an average weight loss of 15.1%, compared with 1.5% for the placebo.Behind the Ozempic and Wegovy drugs to treat diabetes and weight loss, Novo Nordisk became Europe's top company by market cap, though it's now fallen from that perch.Novo Nordisk shares   fell 3% on Monday and have dropped 18% this year, as the Danish drugmaker's trial of a key next-generation drug disappointed investors","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","NVO","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4590","BK1191","03933","BK4585","BK4144","GLP","BK4588","ULIHF","BK4599","BK4007","LU1093756325.SGD","BK4532","IE00BKVL7J92.USD"],"gpt_icon":1},{"id":"2521743606","title":"The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist","url":"https://stock-news.laohu8.com/highlight/detail?id=2521743606","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521743606?lang=en_us&edition=fundamental","pubTime":"2025-03-24 18:02","pubTimestamp":1742810520,"startTime":"0","endTime":"0","summary":"Guangdong, China and Bagsvrd, Denmark, 24 March 2025 –The United Laboratories International Holdings Limited  and Novo Nordisk A/S  today announced that Novo Nordisk and TUL’s wholly-owned subsidiary The United Bio-Technology  Co., Ltd. , have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases.“We are pleased to announce our exclusive license agreement with Novo Nordisk for UBT251. As a leading global biopharmaceutical company, Novo Nordisk holds a strong position in the treatment of chronic diseases,” said Mr. Tsoi Hoi Shan, the Chairman of TUL. “TUL is committed to strengthening its presence in the treatm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/united-laboratories-novo-nordisk-announce-100200123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4590","IE00BKVL7J92.USD","LU1093756168.USD","LU0154236417.USD","IE00BZ1G4Q59.USD","BK4211","BK4585","BK4007","BK4144","GLP","LU1093756325.SGD","UBCP","BK4599","NVO","BK4532"],"gpt_icon":1},{"id":"2521250562","title":"BRIEF-Global Partners LP enters eleventh amendment to credit, security agreements","url":"https://stock-news.laohu8.com/highlight/detail?id=2521250562","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521250562?lang=en_us&edition=fundamental","pubTime":"2025-03-22 05:30","pubTimestamp":1742592658,"startTime":"0","endTime":"0","summary":"BRIEF-Global Partners LP enters eleventh amendment to credit, security agreementsMarch 21  - Global Partners LP GLP.N:GLOBAL PARTNERS LP - ON MARCH 20, ENTERS ELEVENTH AMENDMENT TO CREDIT AND SECURITY AGREEMENTS - SEC FILINGGLOBAL PARTNERS LP - MATURITY DATE OF CREDIT FACILITY EXTENDED TO MARCH 20, 2028 - SEC FILINGSource text: [ID:n0001104659-25-026718]Further company coverage: GLP.N ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nFWN3Q41CF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLP","BK4590","BK4144"],"gpt_icon":0},{"id":"2521250886","title":"Global Partners Lp - on March 20, Enters Eleventh Amendment to Credit and Security Agreements - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2521250886","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521250886?lang=en_us&edition=fundamental","pubTime":"2025-03-22 05:26","pubTimestamp":1742592394,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nFWN3Q41CF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4144","BK4590","GLP"],"gpt_icon":0},{"id":"2521326499","title":"Allurion announces initial results from Allurion Program-GLP-1 combo","url":"https://stock-news.laohu8.com/highlight/detail?id=2521326499","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521326499?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:15","pubTimestamp":1742501755,"startTime":"0","endTime":"0","summary":"Allurion Technologies (ALUR) announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize muscle ma...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/allurion-announces-initial-results-from-allurion-program-glp-1-combo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/allurion-announces-initial-results-from-allurion-program-glp-1-combo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLP","BK4144","ALUR","BK4590","BK4192"],"gpt_icon":0},{"id":"2521915314","title":"Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence","url":"https://stock-news.laohu8.com/highlight/detail?id=2521915314","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521915314?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:05","pubTimestamp":1742501100,"startTime":"0","endTime":"0","summary":"Average Total Weight Loss of 20% With 15% Increase in Lean Body Mass After 8 Months of Combined Therapy. \"I believe combining the Allurion Balloon with low-dose GLP-1 therapy has several advantages,\" said Dr. Luigi Flagiello, bariatric surgeon at Clinica Ruesch who oversaw this case series. \"These results indicate that a combination approach increases weight loss and that by using lower doses of GLP-1s, patients do not experience as many side effects—including muscle wasting—and have improved adherence. Patients may also be benefiting from two distinct physiological impacts: satiety induction from the balloon and reduced hunger from the GLP-1.\". Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, ProcedurelessTM gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare provide","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/allurion-announces-initial-results-combination-200500111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4144","ALUR","BK4192","GLP","BK4590"],"gpt_icon":0},{"id":"2521846996","title":"“GLP-1 Is a Curse Word!” – Jim Cramer on PepsiCo (PEP)’s Snack Struggles","url":"https://stock-news.laohu8.com/highlight/detail?id=2521846996","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521846996?lang=en_us&edition=fundamental","pubTime":"2025-03-20 23:37","pubTimestamp":1742485021,"startTime":"0","endTime":"0","summary":"We recently published a list of Was Jim Cramer Right About These 13 Stocks?In this article, we are going to take a look at where PepsiCo Inc.  stands against other stocks that Jim Cramer discusses.During the latest episode of Mad Money, Jim Cramer expressed his frustration over the negative outlook he believes the White House is projecting about the economy. He explained that while he felt a sense of optimism and wanted to get excited about positive developments in the stock market, he held back.“I wanted to get excited, but you know what I had to do? I had to hold my breath because when this market’s getting ahead of steam going, you know what you can bet on? The president will post something rancorous, dispiriting, and confusing and the market will immediately get put through the meat grinder…It’s not necessary to do this, nor will they highlight anything good that’s going on here. It makes people feel like everything’s terrible, which isn’t true…","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/glp-1-curse-word-jim-153701036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PEP","GLP"],"gpt_icon":0},{"id":"2520316470","title":"Is Global Partners LP (GLP) The Best Pipeline and MLP Stock to Invest In According to Analysts?","url":"https://stock-news.laohu8.com/highlight/detail?id=2520316470","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520316470?lang=en_us&edition=fundamental","pubTime":"2025-03-20 02:19","pubTimestamp":1742408359,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Best Pipeline and MLP Stocks to Invest In According to Analysts. In this article, we are going to take a look at where Global Partners LP  stands against other best pipeline and MLP stocks to invest in according to analysts.The global pipeline market is part of the energy sector, influenced by the demand and supply of energy. According to a report by Fortune Business Insights, the global pipeline transportation market reached a valuation of $20.57 billion in 2023. Forecasts indicate this market will expand to $34.38 billion by 2032. This growth trajectory represents a Compound Annual Growth Rate  of 5.43% throughout the projected period. Notably, North America holds the leading position in the global market in 2023, capturing a 43.32% share.Pipeline companies have underperformed the overall market performance, especially over the past 5 years where TECH firms have been the centre of attention due to the popularity of AI amongst investors. This highlig","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/global-partners-lp-glp-best-181919290.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLP","BK4233","BK4590","BK4024","CAGR","MLP","BK4159","BK4144"],"gpt_icon":0},{"id":"2520139497","title":"PepsiCo, Inc. (PEP): “GLP-1 Is a Curse Word for Pepsi!” – Jim Cramer’s Take on the Snack Giant","url":"https://stock-news.laohu8.com/highlight/detail?id=2520139497","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520139497?lang=en_us&edition=fundamental","pubTime":"2025-03-19 21:53","pubTimestamp":1742392398,"startTime":"0","endTime":"0","summary":"We recently published a list of Jim Cramer Discusses These 12 Stocks & Shares Big Buying Signal. In this article, we are going to take a look at where PepsiCo, Inc.  stands against other best stocks that Jim Cramer discusses.In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer commented on President Trump’s latest set of tariffs. This time around, Trump targeted champagne in a bid to get European countries to reduce their restrictions on American whiskey brands such as Jack Daniel’s. Cramer started out by explaining the effect of the tariffs on the consumer and the general trend in the alcoholic beverage market:. “Used car market unfortunately very much involved in the CPI. It’s gonna be a convoluted sense of world trade. And I think that what people recognize is that there has been a big disadvantage, we’ve been at a big disadvantage in our country. But the President","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pepsico-inc-pep-glp-1-135318518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLP","PEP"],"gpt_icon":0},{"id":"2520530602","title":"Jim Cramer Sees General Mills (GIS) Struggling as GLP-1 Weight Loss Drugs Take Over","url":"https://stock-news.laohu8.com/highlight/detail?id=2520530602","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520530602?lang=en_us&edition=fundamental","pubTime":"2025-03-18 22:51","pubTimestamp":1742309485,"startTime":"0","endTime":"0","summary":"We recently published a list of 8 Stocks in Focus Under Jim Cramer’s Game Plan. In this article, we are going to take a look at where General Mills, Inc.  stands against other stocks in focus under Jim Cramer’s game plan.Jim Cramer, host of Mad Money, offered some important insights to his viewers on Friday, advising them to closely monitor the upcoming Federal Reserve meeting and the earnings reports from companies. However, he also cautioned that irrespective of what the earnings reveal, the direction of the market will largely be determined by President Donald Trump and the Federal Reserve.Cramer explained that Monday will mark a significant moment for understanding consumer behavior, as the February retail sales numbers will be released. He forecasted a sharp decline in consumer spending, which he attributed to growing fears among consumers about job security. Cramer noted that many consumers are left wondering if they might be the next to lose their jobs. He added:. According to C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jim-cramer-sees-general-mills-145125478.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","US7Y.BOND","GIS","BK4212","LU1585245621.USD","US3Y.BOND","US6M.BOND","BK4590","BK4566","US10Y.BOND","US30Y.BOND","LU1989763427.SGD","BK4588","BK4144","US2Y.BOND","LU1989763690.USD","BK4532","LU1430594728.SGD","US5Y.BOND","GLP","US12M.BOND"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GLP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-28","symbol":"GLP","fiscalQuarterEnding":"2024/12","expectedEps":0.24,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740718800000,"reportTimeType":"pre","actualEps":0.52},{"date":"2025-02-10","symbol":"GLP","amount":0.74,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-10","defaultRemindTime":1739197800000,"name":"全球合伙","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-14","payableDate":"2025-02-10","currency":"USD","dateTimestamp":1739163600000,"payDate":"2025-02-14"},{"date":"2024-11-08","symbol":"GLP","amount":0.73,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-08","defaultRemindTime":1731076200000,"name":"全球合伙","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-14","payableDate":"2024-11-08","currency":"USD","dateTimestamp":1731042000000,"payDate":"2024-11-14"},{"market":"US","date":"2024-11-08","symbol":"GLP","fiscalQuarterEnding":"2024/09","expectedEps":1.57,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731042000000,"reportTimeType":"pre","actualEps":1.17},{"date":"2024-08-08","symbol":"GLP","amount":0.72,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-08-08","defaultRemindTime":1723123800000,"name":"全球合伙","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-08-14","payableDate":"2024-08-08","currency":"USD","dateTimestamp":1723089600000,"payDate":"2024-08-14"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GLP\",market:\"US\",,,undefined,":[{"executeDate":"2015-05-04","recordDate":"2015-05-06","paymentDate":"2015-05-15","value":0.68,"currency":"USD"},{"executeDate":"2015-08-03","recordDate":"2015-08-05","paymentDate":"2015-08-14","value":0.6925,"currency":"USD"},{"executeDate":"2015-11-02","recordDate":"2015-11-04","paymentDate":"2015-11-13","value":0.6975,"currency":"USD"},{"executeDate":"2016-02-08","recordDate":"2016-02-10","paymentDate":"2016-02-16","value":0.4625,"currency":"USD"},{"executeDate":"2016-05-04","recordDate":"2016-05-06","paymentDate":"2016-05-16","value":0.4625,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GLP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":2,"updateTime":1741233600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GLP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GLP","date":"2025-04-21","current":18.509538,"percent":0.885273,"low":2.771386,"twenty":4.270877,"median":9.726256,"eighty":15.350956,"high":29.34912,"avg":10.428443,"sd":6.24379,"marketCap":1709337357},"quantilePoints":[{"date":"2020-04-24","current":10.885399,"twenty":6.299451,"median":7.87934,"eighty":11.115597,"marketCap":375415632},{"date":"2020-05-01","current":11.300646,"twenty":6.299659,"median":7.88907,"eighty":11.255307,"marketCap":389736665},{"date":"2020-05-08","current":11.690231,"twenty":6.299659,"median":7.896854,"eighty":11.255307,"marketCap":361461939},{"date":"2020-05-15","current":10.863092,"twenty":6.299659,"median":7.912422,"eighty":11.245121,"marketCap":335886802},{"date":"2020-05-22","current":11.182919,"twenty":6.299659,"median":7.932539,"eighty":11.262234,"marketCap":345775855},{"date":"2020-05-29","current":11.24909,"twenty":6.299659,"median":7.943558,"eighty":11.269162,"marketCap":347821866},{"date":"2020-06-05","current":12.451199,"twenty":6.307959,"median":7.955234,"eighty":11.298028,"marketCap":384991066},{"date":"2020-06-12","current":11.557889,"twenty":6.309309,"median":7.998046,"eighty":11.32112,"marketCap":357369917},{"date":"2020-06-19","current":11.072634,"twenty":6.3117,"median":8.066523,"eighty":11.332667,"marketCap":342365837},{"date":"2020-06-26","current":10.708693,"twenty":6.3117,"median":8.171888,"eighty":11.326893,"marketCap":331112776},{"date":"2020-07-02","current":10.752807,"twenty":6.317715,"median":8.211094,"eighty":11.322275,"marketCap":332476784},{"date":"2020-07-10","current":10.43298,"twenty":6.321861,"median":8.267451,"eighty":11.32112,"marketCap":322587731},{"date":"2020-07-17","current":10.13521,"twenty":6.32825,"median":8.287054,"eighty":11.316433,"marketCap":313380681},{"date":"2020-07-24","current":10.543265,"twenty":6.333279,"median":8.291955,"eighty":11.303569,"marketCap":325997749},{"date":"2020-07-31","current":11.800516,"twenty":6.334178,"median":8.348313,"eighty":11.303569,"marketCap":364871958},{"date":"2020-08-07","current":4.73435,"twenty":6.333279,"median":8.360564,"eighty":11.32112,"marketCap":438154667},{"date":"2020-08-14","current":5.006778,"twenty":6.3117,"median":8.298445,"eighty":11.316433,"marketCap":463367300},{"date":"2020-08-21","current":4.712262,"twenty":6.299659,"median":8.287054,"eighty":11.303569,"marketCap":436110400},{"date":"2020-08-28","current":4.701217,"twenty":6.299607,"median":8.274802,"eighty":11.298552,"marketCap":435088266},{"date":"2020-09-04","current":4.542915,"twenty":6.2824,"median":8.213544,"eighty":11.285346,"marketCap":420437682},{"date":"2020-09-11","current":4.749076,"twenty":6.27606,"median":8.174338,"eighty":11.274368,"marketCap":439517512},{"date":"2020-09-18","current":4.815342,"twenty":6.275736,"median":8.086126,"eighty":11.269162,"marketCap":445650315},{"date":"2020-09-25","current":4.73435,"twenty":6.258044,"median":8.00583,"eighty":11.265698,"marketCap":438154667},{"date":"2020-10-02","current":4.933149,"twenty":6.250305,"median":7.971673,"eighty":11.259925,"marketCap":456553075},{"date":"2020-10-09","current":5.360198,"twenty":6.244429,"median":7.94745,"eighty":11.2525,"marketCap":496075580},{"date":"2020-10-16","current":5.26448,"twenty":6.239772,"median":7.932539,"eighty":11.247278,"marketCap":487217087},{"date":"2020-10-23","current":5.271843,"twenty":6.23717,"median":7.912422,"eighty":11.243223,"marketCap":487898510},{"date":"2020-10-30","current":5.338109,"twenty":6.227089,"median":7.896854,"eighty":11.239367,"marketCap":494031312},{"date":"2020-11-06","current":5.459545,"twenty":6.22179,"median":7.88907,"eighty":11.21862,"marketCap":522855188},{"date":"2020-11-13","current":5.670214,"twenty":6.203808,"median":7.87934,"eighty":11.19873,"marketCap":543030764},{"date":"2020-11-20","current":5.877313,"twenty":6.196135,"median":7.85015,"eighty":11.194013,"marketCap":562864382},{"date":"2020-11-27","current":6.170107,"twenty":6.185826,"median":7.85015,"eighty":11.189536,"marketCap":590905013},{"date":"2020-12-04","current":6.109406,"twenty":6.168749,"median":7.838474,"eighty":11.169685,"marketCap":585091712},{"date":"2020-12-11","current":6.416483,"twenty":6.167844,"median":7.834582,"eighty":11.145422,"marketCap":614500179},{"date":"2020-12-18","current":6.230809,"twenty":6.167844,"median":7.828744,"eighty":11.130907,"marketCap":596718315},{"date":"2020-12-24","current":6.048705,"twenty":6.167844,"median":7.82096,"eighty":11.115597,"marketCap":579278410},{"date":"2020-12-31","current":5.934444,"twenty":6.167844,"median":7.817068,"eighty":11.101741,"marketCap":568335725},{"date":"2021-01-08","current":6.062987,"twenty":6.149862,"median":7.795662,"eighty":11.084422,"marketCap":580646246},{"date":"2021-01-15","current":6.216526,"twenty":6.149862,"median":7.785585,"eighty":11.084422,"marketCap":595350479},{"date":"2021-01-22","current":6.705707,"twenty":6.149862,"median":7.780094,"eighty":11.074992,"marketCap":642198851},{"date":"2021-01-29","current":7.180605,"twenty":6.149862,"median":7.776202,"eighty":11.068208,"marketCap":687679388},{"date":"2021-02-05","current":7.284155,"twenty":6.149862,"median":7.768418,"eighty":11.06411,"marketCap":697596196},{"date":"2021-02-12","current":6.934229,"twenty":6.163202,"median":7.760634,"eighty":11.053134,"marketCap":664084222},{"date":"2021-02-19","current":7.112763,"twenty":6.167321,"median":7.75285,"eighty":11.04396,"marketCap":681182168},{"date":"2021-02-26","current":7.202029,"twenty":6.167844,"median":7.741174,"eighty":11.038761,"marketCap":689731141},{"date":"2021-03-05","current":6.896217,"twenty":6.167844,"median":7.718575,"eighty":11.032407,"marketCap":695214499},{"date":"2021-03-12","current":7.842623,"twenty":6.167844,"median":7.698362,"eighty":11.017031,"marketCap":790622686},{"date":"2021-03-19","current":7.720506,"twenty":6.167844,"median":7.718575,"eighty":11.007626,"marketCap":778311953},{"date":"2021-03-26","current":7.411822,"twenty":6.167844,"median":7.69367,"eighty":11.00501,"marketCap":747193153},{"date":"2021-04-01","current":7.320234,"twenty":6.167844,"median":7.686686,"eighty":10.988222,"marketCap":737960103},{"date":"2021-04-09","current":7.3779,"twenty":6.167844,"median":7.67501,"eighty":10.954813,"marketCap":743773505},{"date":"2021-04-16","current":7.510194,"twenty":6.168749,"median":7.659442,"eighty":10.940212,"marketCap":757110133},{"date":"2021-04-23","current":7.364332,"twenty":6.170107,"median":7.594997,"eighty":10.930856,"marketCap":742405645},{"date":"2021-04-30","current":8.185229,"twenty":6.171613,"median":7.641929,"eighty":10.912383,"marketCap":825161134},{"date":"2021-05-07","current":9.181725,"twenty":6.178654,"median":7.67501,"eighty":10.905455,"marketCap":849502414},{"date":"2021-05-14","current":8.749253,"twenty":6.185826,"median":7.686686,"eighty":10.905455,"marketCap":809489619},{"date":"2021-05-21","current":9.203903,"twenty":6.185826,"median":7.690578,"eighty":10.897433,"marketCap":851554353},{"date":"2021-05-28","current":9.407203,"twenty":6.185826,"median":7.712361,"eighty":10.877257,"marketCap":870363786},{"date":"2021-06-04","current":9.706607,"twenty":6.189262,"median":7.720506,"eighty":10.864653,"marketCap":898064952},{"date":"2021-06-11","current":10.061456,"twenty":6.203126,"median":7.741174,"eighty":10.858681,"marketCap":930895963},{"date":"2021-06-18","current":9.603109,"twenty":6.203644,"median":7.748958,"eighty":10.836624,"marketCap":888489240},{"date":"2021-06-25","current":9.680732,"twenty":6.203808,"median":7.760634,"eighty":10.817799,"marketCap":895671024},{"date":"2021-07-02","current":9.658554,"twenty":6.203808,"median":7.768418,"eighty":10.809851,"marketCap":893619086},{"date":"2021-07-09","current":9.31849,"twenty":6.203808,"median":7.778148,"eighty":10.796921,"marketCap":862156033},{"date":"2021-07-16","current":8.963641,"twenty":6.213362,"median":7.780094,"eighty":10.785892,"marketCap":829325022},{"date":"2021-07-23","current":9.495915,"twenty":6.213362,"median":7.785616,"eighty":10.763835,"marketCap":878571539},{"date":"2021-07-30","current":9.909906,"twenty":6.216526,"median":7.795662,"eighty":10.752807,"marketCap":916874385},{"date":"2021-08-06","current":29.34912,"twenty":6.22179,"median":7.817068,"eighty":10.752807,"marketCap":823536295},{"date":"2021-08-13","current":26.023372,"twenty":6.22179,"median":7.822906,"eighty":10.813084,"marketCap":730215805},{"date":"2021-08-20","current":24.554702,"twenty":6.22179,"median":7.83069,"eighty":10.865043,"marketCap":689004931},{"date":"2021-08-27","current":24.530426,"twenty":6.22179,"median":7.834582,"eighty":10.905455,"marketCap":688323760},{"date":"2021-09-03","current":25.100901,"twenty":6.22179,"median":7.842494,"eighty":10.964493,"marketCap":704331289},{"date":"2021-09-10","current":24.275533,"twenty":6.228856,"median":7.848204,"eighty":11.013201,"marketCap":681171460},{"date":"2021-09-17","current":25.198003,"twenty":6.230622,"median":7.85015,"eighty":11.053134,"marketCap":707055975},{"date":"2021-09-24","current":24.894559,"twenty":6.230772,"median":7.876969,"eighty":11.084422,"marketCap":698541332},{"date":"2021-10-01","current":26.047647,"twenty":6.233421,"median":7.883329,"eighty":11.141011,"marketCap":730896976},{"date":"2021-10-08","current":26.897291,"twenty":6.234318,"median":7.892962,"eighty":11.19642,"marketCap":754737977},{"date":"2021-10-15","current":26.836602,"twenty":6.236185,"median":7.896854,"eighty":11.246674,"marketCap":753035049},{"date":"2021-10-22","current":28.632991,"twenty":6.237348,"median":7.914368,"eighty":11.269162,"marketCap":803441737},{"date":"2021-10-29","current":28.329547,"twenty":6.237865,"median":7.935774,"eighty":11.303569,"marketCap":794927093},{"date":"2021-11-05","current":18.151279,"twenty":6.239408,"median":7.94745,"eighty":11.328048,"marketCap":776838422},{"date":"2021-11-12","current":18.191189,"twenty":6.239772,"median":7.988112,"eighty":11.346522,"marketCap":778546510},{"date":"2021-11-19","current":18.773882,"twenty":6.239772,"median":8.014118,"eighty":11.360961,"marketCap":803484595},{"date":"2021-11-26","current":18.694061,"twenty":6.239772,"median":8.035981,"eighty":11.378852,"marketCap":800068419},{"date":"2021-12-03","current":18.103386,"twenty":6.239772,"median":8.105729,"eighty":11.403489,"marketCap":774788716},{"date":"2021-12-10","current":18.430652,"twenty":6.240495,"median":8.179783,"eighty":11.427136,"marketCap":788795038},{"date":"2021-12-17","current":18.550383,"twenty":6.243048,"median":8.213544,"eighty":11.470285,"marketCap":793919302},{"date":"2021-12-23","current":17.991637,"twenty":6.244429,"median":8.252749,"eighty":11.474686,"marketCap":770006070},{"date":"2021-12-31","current":18.749936,"twenty":6.244429,"median":8.284603,"eighty":11.575574,"marketCap":802459742},{"date":"2022-01-07","current":20.051017,"twenty":6.24581,"median":8.291955,"eighty":11.616705,"marketCap":858143411},{"date":"2022-01-14","current":21.152545,"twenty":6.248234,"median":8.320498,"eighty":11.690231,"marketCap":905286640},{"date":"2022-01-21","current":20.146802,"twenty":6.249277,"median":8.363015,"eighty":11.729858,"marketCap":862242822},{"date":"2022-01-28","current":21.392008,"twenty":6.251718,"median":8.365465,"eighty":11.776801,"marketCap":915535168},{"date":"2022-02-04","current":21.85497,"twenty":6.254157,"median":8.433466,"eighty":11.837284,"marketCap":935348988},{"date":"2022-02-11","current":21.559632,"twenty":6.257754,"median":8.47328,"eighty":11.938846,"marketCap":922709137},{"date":"2022-02-18","current":20.945011,"twenty":6.257851,"median":8.48054,"eighty":12.432666,"marketCap":896404582},{"date":"2022-02-25","current":20.529942,"twenty":6.258237,"median":8.487891,"eighty":12.775373,"marketCap":878640467},{"date":"2022-03-04","current":15.348683,"twenty":6.268592,"median":8.571294,"eighty":13.121553,"marketCap":878174885},{"date":"2022-03-11","current":15.504022,"twenty":6.275496,"median":8.601399,"eighty":13.154839,"marketCap":887062603},{"date":"2022-03-18","current":15.940166,"twenty":6.275736,"median":8.649704,"eighty":13.201441,"marketCap":912016580},{"date":"2022-03-25","current":16.890123,"twenty":6.275736,"median":8.669307,"eighty":13.248042,"marketCap":966368393},{"date":"2022-04-01","current":16.214996,"twenty":6.275736,"median":8.68891,"eighty":13.261356,"marketCap":927741004},{"date":"2022-04-08","current":16.752708,"twenty":6.275736,"median":8.726599,"eighty":13.281328,"marketCap":958506181},{"date":"2022-04-14","current":16.573471,"twenty":6.275736,"median":8.736337,"eighty":13.3013,"marketCap":948251122},{"date":"2022-04-22","current":16.011861,"twenty":6.276168,"median":8.777122,"eighty":13.329261,"marketCap":916118604},{"date":"2022-04-29","current":15.743005,"twenty":6.281175,"median":8.797306,"eighty":13.342575,"marketCap":900736015},{"date":"2022-05-06","current":9.804164,"twenty":6.2824,"median":8.848712,"eighty":13.349233,"marketCap":897659497},{"date":"2022-05-13","current":9.69216,"twenty":6.2824,"median":8.9103,"eighty":13.347901,"marketCap":887404438},{"date":"2022-05-20","current":10.270852,"twenty":6.291454,"median":8.930374,"eighty":13.347901,"marketCap":940388910},{"date":"2022-05-27","current":11.163158,"twenty":6.293718,"median":8.972794,"eighty":13.342575,"marketCap":1022087547},{"date":"2022-06-03","current":10.868211,"twenty":6.294536,"median":8.995202,"eighty":13.341244,"marketCap":995082558},{"date":"2022-06-10","current":10.244717,"twenty":6.297672,"median":9.026396,"eighty":13.341244,"marketCap":937996063},{"date":"2022-06-17","current":7.754474,"twenty":6.299555,"median":9.016925,"eighty":13.33725,"marketCap":709991918},{"date":"2022-06-24","current":8.613179,"twenty":6.299659,"median":8.99034,"eighty":13.331924,"marketCap":788614037},{"date":"2022-07-01","current":8.814788,"twenty":6.299659,"median":8.977241,"eighty":13.322603,"marketCap":807073143},{"date":"2022-07-08","current":8.900658,"twenty":6.299659,"median":8.963641,"eighty":13.313284,"marketCap":814935355},{"date":"2022-07-15","current":8.867057,"twenty":6.299659,"median":8.92485,"eighty":13.306626,"marketCap":811858837},{"date":"2022-07-22","current":9.561487,"twenty":6.300172,"median":8.963641,"eighty":13.3013,"marketCap":875440203},{"date":"2022-07-29","current":10.371656,"twenty":6.303369,"median":8.980096,"eighty":13.299969,"marketCap":949618463},{"date":"2022-08-05","current":3.850073,"twenty":6.303369,"median":8.997729,"eighty":13.29198,"marketCap":927520968},{"date":"2022-08-12","current":4.016293,"twenty":6.299659,"median":8.972794,"eighty":13.281328,"marketCap":967565231},{"date":"2022-08-19","current":3.999245,"twenty":6.293991,"median":8.937993,"eighty":13.278687,"marketCap":963458127},{"date":"2022-08-26","current":3.899797,"twenty":6.2824,"median":8.919306,"eighty":13.268103,"marketCap":939500021},{"date":"2022-09-02","current":4.077383,"twenty":6.275736,"median":8.9103,"eighty":13.268014,"marketCap":982282354},{"date":"2022-09-09","current":4.169728,"twenty":6.275496,"median":8.900658,"eighty":13.268014,"marketCap":1004529167},{"date":"2022-09-16","current":4.014873,"twenty":6.257754,"median":8.857885,"eighty":13.261356,"marketCap":967222973},{"date":"2022-09-23","current":3.607134,"twenty":6.247881,"median":8.814788,"eighty":13.254699,"marketCap":868994737},{"date":"2022-09-30","current":3.51621,"twenty":6.240977,"median":8.791187,"eighty":13.254699,"marketCap":847090183},{"date":"2022-10-07","current":3.916845,"twenty":6.239772,"median":8.777122,"eighty":13.248042,"marketCap":943607125},{"date":"2022-10-14","current":3.740679,"twenty":6.236636,"median":8.755886,"eighty":13.248042,"marketCap":901167051},{"date":"2022-10-21","current":4.087328,"twenty":6.230622,"median":8.734756,"eighty":13.241384,"marketCap":984678164},{"date":"2022-10-28","current":4.250707,"twenty":6.22179,"median":8.716798,"eighty":13.234727,"marketCap":1024037910},{"date":"2022-11-04","current":3.449288,"twenty":6.213362,"median":8.68891,"eighty":13.208098,"marketCap":1095762902},{"date":"2022-11-11","current":3.301892,"twenty":6.203808,"median":8.669307,"eighty":13.201441,"marketCap":1048938349},{"date":"2022-11-18","current":3.311575,"twenty":6.185826,"median":8.649704,"eighty":13.194783,"marketCap":1052014414},{"date":"2022-11-25","current":3.399797,"twenty":6.17312,"median":8.639313,"eighty":13.17348,"marketCap":1080040789},{"date":"2022-12-02","current":3.385811,"twenty":6.167844,"median":8.62969,"eighty":13.162828,"marketCap":1075597583},{"date":"2022-12-09","current":3.518145,"twenty":6.167844,"median":8.601399,"eighty":13.156171,"marketCap":1117637146},{"date":"2022-12-16","current":3.574091,"twenty":6.149862,"median":8.577106,"eighty":13.154839,"marketCap":1135409969},{"date":"2022-12-23","current":3.865656,"twenty":6.146266,"median":8.549709,"eighty":13.144188,"marketCap":1228033720},{"date":"2022-12-30","current":3.740853,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1188386653},{"date":"2023-01-06","current":3.441757,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1093370406},{"date":"2023-01-13","current":3.612823,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1147714231},{"date":"2023-01-20","current":3.620354,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1150106726},{"date":"2023-01-27","current":3.857048,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1225299440},{"date":"2023-02-03","current":4.130323,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1312112845},{"date":"2023-02-10","current":3.93774,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1250933319},{"date":"2023-02-17","current":3.875339,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1231109786},{"date":"2023-02-24","current":3.718259,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1181209167},{"date":"2023-03-03","current":3.363192,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1194165378},{"date":"2023-03-10","current":3.211151,"twenty":6.113691,"median":8.482899,"eighty":13.133536,"marketCap":1140180220},{"date":"2023-03-17","current":2.830086,"twenty":6.097582,"median":8.463126,"eighty":13.133536,"marketCap":1004875645},{"date":"2023-03-24","current":2.875313,"twenty":6.070129,"median":8.365465,"eighty":13.133536,"marketCap":1020934521},{"date":"2023-03-31","current":2.985014,"twenty":6.034422,"median":8.291955,"eighty":13.130873,"marketCap":1059885838},{"date":"2023-04-06","current":2.892634,"twenty":6.016569,"median":8.274802,"eighty":13.130873,"marketCap":1027084729},{"date":"2023-04-14","current":2.896483,"twenty":5.960153,"median":8.185229,"eighty":13.133536,"marketCap":1028451442},{"date":"2023-04-20","current":2.925352,"twenty":5.879004,"median":8.105729,"eighty":13.133536,"marketCap":1038701788},{"date":"2023-04-28","current":2.932088,"twenty":5.726233,"median":7.998046,"eighty":13.136199,"marketCap":1041093536},{"date":"2023-05-05","current":2.771386,"twenty":5.536171,"median":7.943558,"eighty":13.136199,"marketCap":984033273},{"date":"2023-05-12","current":2.975648,"twenty":5.442294,"median":7.932539,"eighty":13.136199,"marketCap":1050433502},{"date":"2023-05-19","current":3.089052,"twenty":5.341054,"median":7.932539,"eighty":13.136199,"marketCap":1090466310},{"date":"2023-05-26","current":2.874844,"twenty":5.253436,"median":7.932539,"eighty":13.136199,"marketCap":1014848784},{"date":"2023-06-02","current":2.846736,"twenty":5.130475,"median":7.932539,"eighty":13.136199,"marketCap":1004926122},{"date":"2023-06-09","current":3.07839,"twenty":5.004569,"median":7.932539,"eighty":13.136199,"marketCap":1086702542},{"date":"2023-06-16","current":3.058036,"twenty":4.918423,"median":7.932539,"eighty":13.136199,"marketCap":1079517166},{"date":"2023-06-23","current":2.916523,"twenty":4.864674,"median":7.935774,"eighty":13.138862,"marketCap":1029561696},{"date":"2023-06-30","current":2.952386,"twenty":4.815342,"median":7.93772,"eighty":13.141525,"marketCap":1042221644},{"date":"2023-07-07","current":2.944631,"twenty":4.771165,"median":7.93772,"eighty":13.141525,"marketCap":1039484358},{"date":"2023-07-14","current":3.066759,"twenty":4.749076,"median":7.93772,"eighty":13.141525,"marketCap":1082596613},{"date":"2023-07-21","current":3.116192,"twenty":4.697536,"median":7.93772,"eighty":13.141525,"marketCap":1100046811},{"date":"2023-07-28","current":3.215057,"twenty":4.671766,"median":7.93772,"eighty":13.141525,"marketCap":1134947207},{"date":"2023-08-04","current":3.279998,"twenty":4.616544,"median":7.93772,"eighty":13.141525,"marketCap":1157871978},{"date":"2023-08-11","current":4.645552,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1075069076},{"date":"2023-08-18","current":4.647031,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1075411237},{"date":"2023-08-25","current":4.663295,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1079175005},{"date":"2023-09-01","current":4.624853,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1070278826},{"date":"2023-09-08","current":4.647031,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1075411237},{"date":"2023-09-15","current":4.775663,"twenty":4.570147,"median":7.93772,"eighty":13.141525,"marketCap":1105179222},{"date":"2023-09-22","current":4.867332,"twenty":4.570147,"median":7.93772,"eighty":13.141525,"marketCap":1126393189},{"date":"2023-09-29","current":5.173389,"twenty":4.570147,"median":7.93772,"eighty":13.141525,"marketCap":1197220464},{"date":"2023-10-06","current":4.475521,"twenty":4.542915,"median":7.93772,"eighty":13.141525,"marketCap":1035720590},{"date":"2023-10-13","current":4.511006,"twenty":4.484012,"median":7.93772,"eighty":13.141525,"marketCap":1043932448},{"date":"2023-10-20","current":4.482914,"twenty":4.482914,"median":7.93772,"eighty":13.141525,"marketCap":1037431394},{"date":"2023-10-27","current":4.534662,"twenty":4.467537,"median":7.94745,"eighty":13.149513,"marketCap":1049407020},{"date":"2023-11-03","current":4.904296,"twenty":4.458666,"median":7.94745,"eighty":13.149513,"marketCap":1134947207},{"date":"2023-11-10","current":7.439549,"twenty":4.458666,"median":7.935774,"eighty":13.149513,"marketCap":1088071185},{"date":"2023-11-17","current":7.820894,"twenty":4.458666,"median":7.896854,"eighty":13.149513,"marketCap":1143844827},{"date":"2023-11-24","current":7.993518,"twenty":4.458666,"median":7.896854,"eighty":13.149513,"marketCap":1169092039},{"date":"2023-12-01","current":8.460278,"twenty":4.458666,"median":7.896854,"eighty":13.149513,"marketCap":1237357955},{"date":"2023-12-08","current":8.743603,"twenty":4.459848,"median":7.902692,"eighty":13.146851,"marketCap":1278795691},{"date":"2023-12-15","current":8.690189,"twenty":4.459848,"median":7.902692,"eighty":13.146851,"marketCap":1270983658},{"date":"2023-12-22","current":9.616802,"twenty":4.459848,"median":7.934448,"eighty":13.146851,"marketCap":1406505433},{"date":"2023-12-29","current":9.686473,"twenty":4.4563,"median":7.940074,"eighty":13.154839,"marketCap":1416695040},{"date":"2024-01-05","current":9.75382,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1426544994},{"date":"2024-01-12","current":9.809556,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1434696679},{"date":"2024-01-19","current":10.16023,"twenty":4.448612,"median":7.939666,"eighty":13.154839,"marketCap":1485984368},{"date":"2024-01-26","current":10.740814,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1570897761},{"date":"2024-02-02","current":10.601474,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1550518547},{"date":"2024-02-09","current":10.963759,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1603504503},{"date":"2024-02-16","current":11.124,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1626940600},{"date":"2024-02-23","current":10.647921,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1557311618},{"date":"2024-03-01","current":11.10678,"twenty":4.4563,"median":7.940074,"eighty":13.154839,"marketCap":1583804596},{"date":"2024-03-08","current":11.32675,"twenty":4.4563,"median":7.94745,"eighty":13.154839,"marketCap":1615171958},{"date":"2024-03-15","current":10.799262,"twenty":4.4563,"median":7.990262,"eighty":13.154839,"marketCap":1539953125},{"date":"2024-03-22","current":11.659401,"twenty":4.4563,"median":8.049544,"eighty":13.154839,"marketCap":1662607257},{"date":"2024-03-28","current":10.571159,"twenty":4.4563,"median":8.239503,"eighty":13.154839,"marketCap":1507426062},{"date":"2024-04-05","current":10.811142,"twenty":4.452456,"median":8.461702,"eighty":13.154839,"marketCap":1541647243},{"date":"2024-04-12","current":11.186562,"twenty":4.452456,"median":8.566313,"eighty":13.154839,"marketCap":1595181367},{"date":"2024-04-19","current":10.81827,"twenty":4.452456,"median":8.624771,"eighty":13.154839,"marketCap":1542663714},{"date":"2024-04-26","current":11.245964,"twenty":4.4563,"median":8.639313,"eighty":13.154839,"marketCap":1603651956},{"date":"2024-05-03","current":11.324374,"twenty":4.4563,"median":8.690189,"eighty":13.154839,"marketCap":1614833134},{"date":"2024-05-10","current":14.682959,"twenty":4.4563,"median":8.734756,"eighty":13.168154,"marketCap":1565364893},{"date":"2024-05-17","current":13.78037,"twenty":4.4563,"median":8.734756,"eighty":13.224197,"marketCap":1469138999},{"date":"2024-05-24","current":14.166489,"twenty":4.4563,"median":8.734756,"eighty":13.241384,"marketCap":1510303519},{"date":"2024-05-31","current":14.905887,"twenty":4.4563,"median":8.734756,"eighty":13.248042,"marketCap":1589131510},{"date":"2024-06-07","current":15.724962,"twenty":4.4563,"median":8.734756,"eighty":13.254699,"marketCap":1676453895},{"date":"2024-06-14","current":15.619789,"twenty":4.452456,"median":8.72747,"eighty":13.254699,"marketCap":1665241293},{"date":"2024-06-21","current":14.485195,"twenty":4.448612,"median":8.720183,"eighty":13.254699,"marketCap":1544281101},{"date":"2024-06-28","current":14.60949,"twenty":4.437079,"median":8.698559,"eighty":13.248042,"marketCap":1557532358},{"date":"2024-07-05","current":14.552123,"twenty":4.437079,"median":8.698559,"eighty":13.254699,"marketCap":1551416394},{"date":"2024-07-12","current":13.854157,"twenty":4.437079,"median":8.698559,"eighty":13.254699,"marketCap":1477005489},{"date":"2024-07-15","current":13.586443,"twenty":4.437079,"median":8.698559,"eighty":13.254699,"marketCap":1448464320},{"date":"2024-08-02","current":13.149816,"twenty":4.293661,"median":8.639313,"eighty":12.179123,"marketCap":1401915033},{"date":"2024-08-09","current":12.65362,"twenty":4.293661,"median":8.639313,"eighty":12.333841,"marketCap":1357404400},{"date":"2024-08-16","current":12.71449,"twenty":4.293661,"median":8.639313,"eighty":12.422884,"marketCap":1363934183},{"date":"2024-08-23","current":13.275377,"twenty":4.293661,"median":8.639313,"eighty":12.626454,"marketCap":1424102779},{"date":"2024-08-30","current":14.261656,"twenty":4.293661,"median":8.639313,"eighty":13.112996,"marketCap":1529904861},{"date":"2024-09-06","current":13.281679,"twenty":4.293661,"median":8.639313,"eighty":13.211726,"marketCap":1424778831},{"date":"2024-09-13","current":13.861472,"twenty":4.293661,"median":8.639313,"eighty":13.294349,"marketCap":1486975582},{"date":"2024-09-20","current":13.839415,"twenty":4.293661,"median":8.639313,"eighty":13.376841,"marketCap":1484609401},{"date":"2024-09-27","current":14.00327,"twenty":4.293661,"median":8.639313,"eighty":13.543138,"marketCap":1502186744},{"date":"2024-10-04","current":14.854053,"twenty":4.293661,"median":8.639313,"eighty":13.653503,"marketCap":1593453715},{"date":"2024-10-11","current":14.854053,"twenty":4.293661,"median":8.639313,"eighty":13.84826,"marketCap":1593453715},{"date":"2024-10-18","current":14.737464,"twenty":4.293661,"median":8.639313,"eighty":13.994199,"marketCap":1580946760},{"date":"2024-10-25","current":15.008455,"twenty":4.293661,"median":8.639313,"eighty":14.123548,"marketCap":1610016980},{"date":"2024-10-31","current":14.655537,"twenty":4.293661,"median":8.639313,"eighty":14.202306,"marketCap":1572158088},{"date":"2024-11-08","current":15.118742,"twenty":4.28479,"median":8.64118,"eighty":14.37096,"marketCap":1621847884},{"date":"2024-11-15","current":13.409306,"twenty":4.28479,"median":8.692753,"eighty":14.37096,"marketCap":1673883715},{"date":"2024-11-22","current":14.009118,"twenty":4.28479,"median":8.746428,"eighty":14.37096,"marketCap":1748758223},{"date":"2024-11-29","current":15.251971,"twenty":4.28479,"median":8.78252,"eighty":14.384136,"marketCap":1903903601},{"date":"2024-12-06","current":15.416785,"twenty":4.28479,"median":8.81344,"eighty":14.484602,"marketCap":1924477227},{"date":"2024-12-13","current":14.881817,"twenty":4.28479,"median":8.908125,"eighty":14.552123,"marketCap":1857697260},{"date":"2024-12-20","current":12.709526,"twenty":4.28479,"median":8.950817,"eighty":14.552123,"marketCap":1586530122},{"date":"2024-12-27","current":12.995923,"twenty":4.28479,"median":9.012663,"eighty":14.552123,"marketCap":1622281013},{"date":"2025-01-03","current":12.674402,"twenty":4.28479,"median":9.065008,"eighty":14.552123,"marketCap":1582145578},{"date":"2025-01-10","current":12.901358,"twenty":4.275919,"median":9.188137,"eighty":14.552123,"marketCap":1610476474},{"date":"2025-01-17","current":14.179335,"twenty":4.275919,"median":9.277741,"eighty":14.552123,"marketCap":1770006394},{"date":"2025-01-24","current":13.960485,"twenty":4.275919,"median":9.31881,"eighty":14.552123,"marketCap":1742687317},{"date":"2025-01-31","current":15.316816,"twenty":4.275919,"median":9.382279,"eighty":14.568402,"marketCap":1911998142},{"date":"2025-02-07","current":15.738305,"twenty":4.275919,"median":9.466344,"eighty":14.652386,"marketCap":1964612662},{"date":"2025-02-14","current":15.435698,"twenty":4.275919,"median":9.483084,"eighty":14.687048,"marketCap":1926838135},{"date":"2025-02-21","current":16.178708,"twenty":4.275919,"median":9.514397,"eighty":14.715407,"marketCap":2019588089},{"date":"2025-02-28","current":15.284394,"twenty":4.275919,"median":9.568033,"eighty":14.816241,"marketCap":1907950871},{"date":"2025-03-07","current":19.286086,"twenty":4.270877,"median":9.582779,"eighty":14.884457,"marketCap":1781050742},{"date":"2025-03-14","current":19.942323,"twenty":4.270877,"median":9.582779,"eighty":14.985042,"marketCap":1841653603},{"date":"2025-03-21","current":19.862116,"twenty":4.270877,"median":9.595365,"eighty":15.085182,"marketCap":1834246586},{"date":"2025-03-28","current":19.719932,"twenty":4.270877,"median":9.649313,"eighty":15.125044,"marketCap":1821115967},{"date":"2025-04-04","current":20.186589,"twenty":4.270877,"median":9.689317,"eighty":15.233006,"marketCap":1864211334},{"date":"2025-04-11","current":16.708531,"twenty":4.275919,"median":9.707094,"eighty":15.273586,"marketCap":1543016172},{"date":"2025-04-17","current":18.524121,"twenty":4.275919,"median":9.710303,"eighty":15.333027,"marketCap":1710684087},{"date":"2025-04-21","current":18.509538,"twenty":4.270877,"median":9.726256,"eighty":15.350956,"marketCap":1709337357}],"updateTime":1745355810256}}}